Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial

Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial

ABSTRACT Background With the elevated level of NAFLD prevalence, the incidence of diabetes, hypertension, metabolic syndrome and other diseases is also significantly elevated. GLP‐1RA can exert weight loss, glucose‐lowering effects and various nonglycaemic effects. However, the relationship between...

Full description

Saved in:
Bibliographic Details
Main Authors: Chuanfeng Liu, Yu Xin, Yajing Huang, Lili Xu, Ruizhi Zhou, Yangang Wang, Wei Wang
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
GLP‐1
NAFLD
T2DM
Online Access:https://doi.org/10.1002/edm2.70021
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items